Development and Characterization of Docetaxel loaded Anti-FGFR-1Modified Solid Lipid Nanoparticles for Breast Cancer Targeting

Surface modification of anticancer drug loaded particulate carriers using growth factor receptor inhibitors is an established approach to avoid dose related toxicity of anticancer drugs by selective distribution. AntiFGFR 1 is one such approach that offers an excellent drug targeting to breast cancer cells because of it’s over expression on the primary tumour as well as on metastatic sites. In our present study, anti-FGFR-1 monoclonal antibody appended docetaxel loaded solid lipid nanoparticles were developed using tristearin and were evaluated. Different formulation conditions were optimized and evaluated for the preparation of anti FGFR-1-conjugated lipid nanoparticles. The integrity of anti-FGFR-1 antibody conjugated on the lipid nanoparticles surface was analysed by SDS-PAGE and was confirmed by comparing it with the native antiFGFR-1 antibody. Biological activity study conducted on MDA-MB-453 cell lines demonstrated that the antiFGFR-1 antibody conjugated lipid nanoparticles can effectively target breast cancer cells and exhibited good cytotoxicity.